Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective...

PathoQuest named 32nd most inventive start-up in France

100brevets.tech - Inventors of the French Tech Awards - has ranked PathoQuest as the 32nd most inventive start-up based in France and the 7th ranked MedTech company. See the list in as reported by Forbes at http://bit.ly/pathoquest-no32. .    ...

PathoQuest joins MabDesign

PathoQuest is now a member of MabDesign, a membership organization dedicated to the creation of a unique environment that allows the economic development and growth of the French industrial sector in the field of therapeutic antibody and immunotherapy.  

PathoQuest achieves Illumina Propel Certification

PathoQuest is pleased to announce that it has received Propel Certification from Illumina after successfully completing the requirements for achieving this recognition. This included demonstrating the ability to produce high-quality data on the NexSeq System following...